Pharma & Bio
Business·Industry
[Exclusive] Peptron, Inc.’s Hopes for ‘Once-a-Month Mounjaro’ Shaken; “No Terzepatide in Joint Research with Lilly”
Choi Ho-il, CEO of Peptron, Inc. (Photo: E-Daily DB Inc.)
“In our joint research with Company L, we are developing an entirely different peptide formulation together, and Tuzepatide is not include…
Business·Industry
Amicogen, Inc. Faces Controversy Over Transfer of Management Control to Newly Established Subsidiary via 10 Billion Won Capital Increase… “Explanation to Follow After Payment”
There is widespread speculation in the industry regarding Amicogen, Inc.(092040)’s plan to transfer management control to a newly established entity through a 10 billion won third-party private placem…
Lifestyle
NEXTBIOMEDICAL CO., LTD. to Launch New Clinical Trial for ‘Nexphere F’... ‘Unlimited Expansion of Embolization Platform Draws Attention’
Innovative biomedicine company #NEXTBIOMEDICAL CO., LTD. is leading a paradigm shift in the medical device market with “Nexsphere-FTM,” a treatment for knee osteoarthritis developed in-house. Building…
Lifestyle
"The Era of Adopting Good Technology Is Over"... DaewonPharmaceutical's Open Innovation Approach Through Partnerships with ILDONG PHARM, Tium, and Farmus
“In the past, bringing in good technology was what gave us a competitive edge. Things are different now. The real competitive edge lies in how successfully we develop the technology we’ve brought in.”…
Venture
"Composed of Over 100 Doctors": Which K-Bio Company Has Caught Ad Partners' Attention?
The private investment consortium Ad Partners consists of about 100 members. Whenever an investment opportunity arises in a promising company, Ad Partners forms a private project fund with 49 or fewer…
KOSDAQ
Lemon Healthcare Rebounds to Limit-Up on Second Trading Day; D&D Pharmatech and PharmaResearch Also Gain [K-Bio Pulse]
South Korea’s pharmaceutical and biotech sector posted broad gains on Tuesday despite heightened market volatility that triggered a sell-side sidecar on the benchmark stock market early in the session…
KOSDAQ
Lemon Healthcare Sees 'Reversal' Upward on Second Trading Day… D&D Pharmatech Inc. and Pharmaresearch Also Strong [Bio Spotlight]
On the 7th, the domestic pharmaceutical and biotech sector showed an overall upward trend despite significant volatility early in the session, including the activation of the sell-side circuit breaker…
Technology
[In-Depth Look at Genomictree Inc.] ③ 20 Years of Methylation Data… The Next Move Is ‘Therapeutics’
Genomictree Inc.(228760)is known in the market as the developer of “EarlyTec-C,” an early-stage colorectal cancer diagnostic test, and “EarlyTec-B,” an early-stage bladder cancer diagnostic test. Howe…
Technology
[In-Depth Look at Genomictree Inc.] (2) EarlyTech-B Is Not the End… Why “Plus” Is Even More Promising
Genomictree Inc.(228760)’s bladder cancer diagnostic device, EarlyTec-B, obtained a manufacturing license from the Ministry of Food and Drug Safety last January and simultaneously secured CE-IVDR cert…
Technology
[In-Depth Look at Genomictree Inc.] ① A Hail-Mary Move That Sacrificed Blood… 20 Years of Perseverance That Led to the Creation of ‘EarlyTec-C’
The flagship product of Genomictree Inc.(228760), a domestic in vitro molecular diagnostics company, is the “EarlyTec-C,” a device for the early diagnosis of colorectal cancer. Although it received ap…